{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:46:46Z","timestamp":1766180806967},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11910-015-0598-1","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T08:22:14Z","timestamp":1444810934000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Atypical Optic Neuritis"],"prefix":"10.1007","volume":"15","author":[{"given":"Eric D.","family":"Gaier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Boudreault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph F.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Falardeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean M.","family":"Cestari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"key":"598_CR1","volume-title":"Optic neuritis and its differential diagnosis","author":"GD Perkin","year":"1979","unstructured":"Perkin GD, Rose CF. Optic neuritis and its differential diagnosis. Oxford: Oxford University Press; 1979."},{"issue":"12","key":"598_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","author":"Group Ons","year":"1991","unstructured":"Group Ons. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12):1673\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"Pt 3","key":"598_CR3","first-page":"230","volume":"103","author":"WI Mcdonald","year":"1983","unstructured":"Mcdonald WI. Doyne Lecture. The significance of optic neuritis. Trans Ophthalmol Soc U K. 1983;103(Pt 3):230\u201346.","journal-title":"Trans Ophthalmol Soc U K"},{"issue":"12","key":"598_CR4","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/archopht.1991.01080120052024","volume":"109","author":"JF Rizzo III","year":"1991","unstructured":"Rizzo III JF, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol. 1991;109(12):1668\u201372.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"598_CR5","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0161-6420(02)01148-X","volume":"109","author":"JF Rizzo III","year":"2002","unstructured":"Rizzo III JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(9):1679\u201384.","journal-title":"Ophthalmology"},{"issue":"9","key":"598_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson Jr MM, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"598_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","volume":"115","author":"Group Ons","year":"2008","unstructured":"Group Ons. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115(6):1079\u201382.","journal-title":"Ophthalmology"},{"issue":"11","key":"598_CR8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","volume":"101","author":"RW Beck","year":"1994","unstructured":"Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology. 1994;101(11):1771\u20138.","journal-title":"Ophthalmology"},{"key":"598_CR9","volume-title":"Neuro-ophthalmology: diagnosis and management","author":"GT Liu","year":"2001","unstructured":"Liu GT, Volpe NJ, Galetta SL. Neuro-ophthalmology: diagnosis and management. 2nd ed. Philadelphia: W.B. Saunders; 2001.","edition":"2"},{"issue":"6","key":"598_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/archopht.1953.00920030729007","volume":"50","author":"S Gartner","year":"1953","unstructured":"Gartner S. Optic neuropathy in multiple sclerosis. Optic Neuritis Ama Arch Ophthalmol. 1953;50(6):718\u201326.","journal-title":"Optic Neuritis Ama Arch Ophthalmol"},{"issue":"4","key":"598_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0002-9394(54)92198-4","volume":"37","author":"A Schlossman","year":"1954","unstructured":"Schlossman A, Phillips CC. Optic neuritis in relation to demyelinating diseases; a clinical study. Am J Ophthalmol. 1954;37(4):487\u201394.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"598_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.29.2.208","volume":"29","author":"MM Cohen","year":"1979","unstructured":"Cohen MM, Lessell S, Wolf PA. A prospective study of the risk of developing multiple sclerosis in uncomplicated optic neuritis. Neurology. 1979;29(2):208\u201313.","journal-title":"Neurology"},{"issue":"2","key":"598_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1212\/WNL.38.2.185","volume":"38","author":"JF Rizzo III","year":"1988","unstructured":"Rizzo III JF, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988;38(2):185\u201390.","journal-title":"Neurology"},{"issue":"5","key":"598_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","volume":"49","author":"G Ons","year":"1997","unstructured":"Ons G. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology. 1997;49(5):1404\u201313.","journal-title":"Neurology"},{"issue":"6","key":"598_CR15","first-page":"727","volume":"65","author":"Group Ons","year":"2008","unstructured":"Group Ons. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727\u201332.","journal-title":"Arch Neurol"},{"issue":"7","key":"598_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/archopht.121.7.944","volume":"121","author":"RW Beck","year":"2003","unstructured":"Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"598_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archopht.126.7.996","volume":"126","author":"NJ Volpe","year":"2008","unstructured":"Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126(7):996\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"598_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000069408","volume":"18","author":"DS Goodin","year":"1999","unstructured":"Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999;18(2):53\u201363.","journal-title":"Neuroepidemiology"},{"issue":"11","key":"598_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/archopht.1997.01100160578009","volume":"115","author":"JE Warner","year":"1997","unstructured":"Warner JE, Lessell S, Rizzo III JF, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Arch Ophthalmol. 1997;115(11):1408\u201310.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"598_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0002-9394(14)72557-7","volume":"118","author":"SS Hayreh","year":"1994","unstructured":"Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118(6):766\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"598_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jsm.12726","volume":"12","author":"UB Campbell","year":"2015","unstructured":"Campbell UB, Walker AM, Gaffney M, Petronis KR, Creanga D, Quinn S, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139\u201351. Campbell et al. were the first to demonstrate a connection between phosphodiesterase 5 inhibitor use and NAION. They found among NAION patients who use these drugs that there was a twofold increase in the likelihood of use within five half-lives of symptom onset in definitive cases.","journal-title":"J Sex Med"},{"issue":"3","key":"598_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmg.2007.054270","volume":"46","author":"P Yu-Wai-Man","year":"2009","unstructured":"Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46(3):145\u201358.","journal-title":"J Med Genet"},{"issue":"4","key":"598_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/WNO.0b013e3181f68c19","volume":"30","author":"SL Galetta","year":"2010","unstructured":"Galetta SL, Cornblath WT. Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment? J Neuroophthalmol. 2010;30(4):376\u20138. Discussion 8\u20139.","journal-title":"J Neuroophthalmol"},{"issue":"8","key":"598_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019\u201332.","journal-title":"Eur J Neurol"},{"issue":"9","key":"598_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"9451","key":"598_CR26","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"issue":"Pt 5","key":"598_CR27","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235\u201343.","journal-title":"Brain"},{"issue":"1\u20132","key":"598_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","volume":"298","author":"S Jarius","year":"2010","unstructured":"Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1\u20132):158\u201362.","journal-title":"J Neurol Sci"},{"issue":"9","key":"598_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, Mckeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IGG assays. Neurology. 2012;78(9):665\u201371. Discussion 9.","journal-title":"Neurology"},{"issue":"10","key":"598_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"23","key":"598_CR31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1212\/01.wnl.0000313843.78606.cd","volume":"70","author":"G Giovannoni","year":"2008","unstructured":"Giovannoni G. To test or not to test: NMO-IgG and optic neuritis. Neurology. 2008;70(23):2192\u20133.","journal-title":"Neurology"},{"key":"598_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.","journal-title":"J Neuroinflammation"},{"key":"598_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","volume":"12","author":"A Probstel","year":"2015","unstructured":"Probstel A, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"598_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276\u201383. Kitley et al. distinguished NMO patients who are NMO-IgG positive and those who are NMO-IgG negative, anti-MOG positive. They highlighted the clinical differences between these groups.","journal-title":"JAMA Neurol"},{"issue":"7","key":"598_CR35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R Hoftberger","year":"2015","unstructured":"Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21(7):866\u201374.","journal-title":"Mult Scler"},{"issue":"4","key":"598_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007766","volume":"5","author":"H Nakajima","year":"2015","unstructured":"Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4), E007766.","journal-title":"BMJ Open"},{"issue":"2","key":"598_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/WNO.0b013e31823c9b6c","volume":"32","author":"T Kezuka","year":"2012","unstructured":"Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol. 2012;32(2):107\u201310.","journal-title":"J Neuroophthalmol"},{"issue":"23","key":"598_CR38","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197\u2013200.","journal-title":"Neurology"},{"issue":"1","key":"598_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","volume":"126","author":"RM Papais-Alvarenga","year":"2008","unstructured":"Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"598_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324\u201330.","journal-title":"JAMA Neurol"},{"issue":"15","key":"598_CR41","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302\u20136.","journal-title":"Neurology"},{"issue":"6","key":"598_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, Mckeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IGG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol"},{"issue":"6","key":"598_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/sj.eye.6702730","volume":"21","author":"Y Murakami","year":"2007","unstructured":"Murakami Y, Yoshida S, Yoshikawa H, Yamaji Y, Ikeda Y, Ueno A, et al. CRMP-5-IGG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond). 2007;21(6):860\u20132.","journal-title":"Eye (Lond)"},{"issue":"5","key":"598_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.survophthal.2012.09.001","volume":"58","author":"E Rahimy","year":"2013","unstructured":"Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58(5):430\u201358.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"598_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","volume":"49","author":"Z Yu","year":"2001","unstructured":"Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146\u201354.","journal-title":"Ann Neurol"},{"issue":"2","key":"598_CR46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/1531-8249(20010201)49:2<214::AID-ANA41>3.0.CO;2-W","volume":"49","author":"JC Antoine","year":"2001","unstructured":"Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49(2):214\u201321.","journal-title":"Ann Neurol"},{"issue":"3","key":"598_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/01.wno.0000235578.80051.0e","volume":"26","author":"R Sheorajpanday","year":"2006","unstructured":"Sheorajpanday R, Slabbynck H, Van De Sompel W, Galdermans D, Neetens I, De Deyn PP. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):168\u201372.","journal-title":"J Neuroophthalmol"},{"issue":"8","key":"598_CR48","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00415-006-0471-x","volume":"254","author":"A Ares-Luque","year":"2007","unstructured":"Ares-Luque A, Garcia-Tunon LA, Saiz A, Cabezas BC, Hernandez-Echebarria LE, Franco M, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol. 2007;254(8):1131\u20132.","journal-title":"J Neurol"},{"issue":"3","key":"598_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.wno.0000235567.73389.c3","volume":"26","author":"PC Calvert","year":"2006","unstructured":"Calvert PC. A CR(I)MP in the optic nerve: recognition and implications of paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):165\u20137.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"598_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ccm.2008.03.013","volume":"29","author":"OP Sharma","year":"2008","unstructured":"Sharma OP. Sarcoidosis around the world. Clin Chest Med. 2008;29(3):357\u201363. Vii.","journal-title":"Clin Chest Med"},{"issue":"10 Pt 1","key":"598_CR51","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","volume":"164","author":"RP Baughman","year":"2001","unstructured":"Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager Jr H, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"598_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","volume":"92","author":"JP Zajicek","year":"1999","unstructured":"Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis\u2014diagnosis and management. QJM. 1999;92(2):103\u201317.","journal-title":"QJM"},{"issue":"3","key":"598_CR53","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00041327-200309000-00002","volume":"23","author":"LP Frohman","year":"2003","unstructured":"Frohman LP, Guirgis M, Turbin RE, Bielory L. Sarcoidosis of the anterior visual pathway: 24 new cases. J Neuroophthalmol. 2003;23(3):190\u20137.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"598_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/08820530802007382","volume":"23","author":"JJ Koczman","year":"2008","unstructured":"Koczman JJ, Rouleau J, Gaunt M, Kardon RH, Wall M, Lee AG. Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol. 2008;23(3):157\u201368.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"598_CR55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10384-006-0413-2","volume":"51","author":"T Kawaguchi","year":"2007","unstructured":"Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol. 2007;51(2):121\u20136.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"598_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1378\/chest.109.2.535","volume":"109","author":"OP Sharma","year":"1996","unstructured":"Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109(2):535\u20139.","journal-title":"Chest"},{"issue":"1","key":"598_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MEG.0b013e32834c7b71","volume":"24","author":"J Cremers","year":"2012","unstructured":"Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol. 2012;24(1):17\u201324.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"598_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.intimp.2015.01.015","volume":"25","author":"S Gungor","year":"2015","unstructured":"Gungor S, Ozseker F, Yalcinsoy M, Akkaya E, Can G, Eroglu H, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"598_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0033-8389(05)70079-8","volume":"37","author":"MF Mafee","year":"1999","unstructured":"Mafee MF, Dorodi S, Pai E. Sarcoidosis of the eye and central orbit nervous system role of MR imaging. Radiol Clin N Am. 1999;37(1):73\u201387. X.","journal-title":"Radiol Clin N Am"},{"issue":"3","key":"598_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/1450-1147.136731","volume":"12","author":"B Vettiyil","year":"2013","unstructured":"Vettiyil B, Gupta N, Kumar R. Positron emission tomography imaging in sarcoidosis. World J Nucl Med. 2013;12(3):82\u20136.","journal-title":"World J Nucl Med"},{"issue":"1","key":"598_CR61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/WNO.0000000000000170","volume":"35","author":"LP Frohman","year":"2015","unstructured":"Frohman LP. Treatment of neuro-ophthalmic sarcoidosis. J Neuroophthalmol. 2015;35(1):65\u201372. Frohman reviewed the literature on treatment of sarcoidosis affecting the visual system. This rare and heterogeneous disorder is not amenable to systematic study.","journal-title":"J Neuroophthalmol"},{"issue":"Pt 2","key":"598_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awg045","volume":"126","author":"D Kidd","year":"2003","unstructured":"Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126(Pt 2):276\u201384.","journal-title":"Brain"},{"issue":"1","key":"598_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","volume":"26","author":"A Petzold","year":"2014","unstructured":"Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014;26(1):17\u201326. Petzold and Plant reviewed 122 cases of CRION published in the literature over the prior 10\u00a0years. They outlined consistent clinical features that support CRION as a distinct entity, propose diagnostic criteria, and outline treatment plans.","journal-title":"J Neurol"},{"issue":"8","key":"598_CR64","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/archopht.1985.01050080055019","volume":"103","author":"S Doro","year":"1985","unstructured":"Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropathy. Arch Ophthalmol. 1985;103(8):1143\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"598_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s004170050223","volume":"237","author":"H Mikkila","year":"1999","unstructured":"Mikkila H, Karma A, Viljanen M, Seppala I. The laboratory diagnosis of ocular Lyme borreliosis. Graefes Arch Clin Exp Ophthalmol. 1999;237(3):225\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"598_CR66","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0161-6420(99)00128-1","volume":"107","author":"HO Mikkila","year":"2000","unstructured":"Mikkila HO, Seppala IJ, Viljanen MK, Peltomaa MP, Karma A. The expanding clinical spectrum of ocular Lyme borreliosis. Ophthalmology. 2000;107(3):581\u20137.","journal-title":"Ophthalmology"},{"issue":"2","key":"598_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01.WNO.0000166060.35366.70","volume":"25","author":"P Sibony","year":"2005","unstructured":"Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol. 2005;25(2):71\u201382.","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"598_CR68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/01.wnl.0000320128.51338.6a","volume":"71","author":"DJ Lanska","year":"2008","unstructured":"Lanska DJ. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology. 2008;71(2):150. Author Reply -1.","journal-title":"Neurology"},{"issue":"11","key":"598_CR69","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.ophtha.2006.05.048","volume":"113","author":"JR Chao","year":"2006","unstructured":"Chao JR, Khurana RN, Fawzi AA, Reddy HS, Rao NA. Syphilis: reemergence of an old adversary. Ophthalmology. 2006;113(11):2074\u20139.","journal-title":"Ophthalmology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-015-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-015-0598-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-015-0598-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-015-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:30:00Z","timestamp":1581960600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-015-0598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s11910-015-0598-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]},"assertion":[{"value":"14 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Eric D. Gaier, Katherine Boudreault, Julie Falardeau, and Dean M. Cestari declare that they have no conflict of interest.Joseph F. Rizzo III owns equity in Bionic Eye Technologies and Visus Technologies, which are working on an implanted and portable device for the blind, respectively. Dr. Rizzo also serves as Medical Director for Neurology and Ophthalmology for Magic Leap, Inc., which is developing a head-mounted \u201cgaming\u201d device.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"76"}}